Literature DB >> 21756875

The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice.

Katsunori Nonogaki1, Marina Suzuki, Marin Sanuki, Mamoru Wakameda, Tomohiro Tamari.   

Abstract

Glucagon-like peptide 1 (GLP-1), an insulinotropic gastrointestinal peptide produced mainly from intestinal endocrine L-cells, and liraglutide, a GLP-1 receptor (GLP-1R) agonist, induce satiety. The serotonin 5-HT2C receptor (5-HT2CR) and melanoroctin-4 receptor (MC4R) are involved in the regulation of food intake. Here we show that systemic administration of GLP-1 (50 and 200μg/kg)-induced anorexia was blunted in mice with a 5HT2CR null mutation, and was attenuated in mice with a heterozygous MC4R mutation. On the other hand, systemic administration of liraglutide (50 and 100μg/kg) suppressed food intake in mice lacking 5-HT2CR, mice with a heterozygous mutation of MC4R and wild-type mice matched for age. Moreover, once-daily consecutive intraperitoneal administration of liraglutide (100μg/kg) over 3days significantly suppressed daily food intake and body weight in mice with a heterozygous mutation of MC4R as well as wild-type mice. These findings suggest that GLP-1 and liraglutide induce anorexia via different central pathways.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756875     DOI: 10.1016/j.bbrc.2011.06.175

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Dietary Protein Modifies the Effect of the MC4R Genotype on 2-Year Changes in Appetite and Food Craving: The POUNDS Lost Trial.

Authors:  Tao Huang; Yan Zheng; Adela Hruby; Donald A Williamson; George A Bray; Yiru Shen; Frank M Sacks; Lu Qi
Journal:  J Nutr       Date:  2017-02-01       Impact factor: 4.798

2.  Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6.

Authors:  Rozita Shirazi; Vilborg Palsdottir; Jim Collander; Fredrik Anesten; Heike Vogel; Fanny Langlet; Alexander Jaschke; Annette Schürmann; Vincent Prévot; Ruijin Shao; John-Olov Jansson; Karolina Patrycja Skibicka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-18       Impact factor: 11.205

3.  Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.

Authors:  Rozita H Anderberg; Jennifer E Richard; Kim Eerola; Lorena López-Ferreras; Elin Banke; Caroline Hansson; Hans Nissbrandt; Filip Berqquist; Fiona M Gribble; Frank Reimann; Ingrid Wernstedt Asterholm; Christophe M Lamy; Karolina P Skibicka
Journal:  Diabetes       Date:  2017-01-05       Impact factor: 9.461

4.  Liraglutide suppresses the plasma levels of active and des-acyl ghrelin independently of active glucagon-like Peptide-1 levels in mice.

Authors:  Katsunori Nonogaki; Marina Suzuki
Journal:  ISRN Endocrinol       Date:  2013-08-13

5.  Serotonergic modulation of the activity of GLP-1 producing neurons in the nucleus of the solitary tract in mouse.

Authors:  Marie K Holt; Ida J Llewellyn-Smith; Frank Reimann; Fiona M Gribble; Stefan Trapp
Journal:  Mol Metab       Date:  2017-06-07       Impact factor: 7.422

6.  Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion.

Authors:  Brandon L Panaro; Bernardo Yusta; Dianne Matthews; Jacqueline A Koehler; Youngmi Song; Darleen A Sandoval; Daniel J Drucker
Journal:  Mol Metab       Date:  2020-04-09       Impact factor: 7.422

Review 7.  The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases.

Authors:  Katsunori Nonogaki
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

8.  Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: A case series.

Authors:  Mila S Welling; Cornelis J de Groot; Lotte Kleinendorst; Bibian van der Voorn; Jan Steven Burgerhart; Eline S van der Valk; Mieke M van Haelst; Erica L T van den Akker; Elisabeth F C van Rossum
Journal:  Clin Obes       Date:  2021-07-21

9.  Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice.

Authors:  Katsunori Nonogaki; Miki Hazama; Noriko Satoh
Journal:  Biomed Res Int       Date:  2014-04-07       Impact factor: 3.411

10.  Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice.

Authors:  Katsunori Nonogaki; Takao Kaji
Journal:  J Diabetes Res       Date:  2018-02-01       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.